A J Pantuck1, A Zisman, A S Belldegrun. 1. Department of Urology, University of California School of Medicine, Los Angeles, California, USA.
Abstract
PURPOSE: Our understanding of the natural history of renal cell carcinoma, the role of nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are evolving and being integrated with advances in classification and staging. We reviewed the relevant literature to clarify these pertinent questions and provide a current review of the changes in the epidemiology, treatment and prognosis of patients with renal cell carcinoma. MATERIALS AND METHODS: We comprehensively reviewed the peer reviewed literature on the current management of and results of treatment for renal cell carcinoma. RESULTS: The incidence of and mortality from renal cell carcinoma have continuously increased during the last 50 years. Despite this increase in the number of new patients and consequently the number of deaths yearly the percent of those surviving for 5 years has notably improved. Factors related to improved survival include advances in renal imaging, earlier diagnosis, improved staging, better understanding of prognostic indicators, refinement in surgical technique and the introduction of immunotherapy approaches for advanced disease. CONCLUSIONS: Currently patients with localized and metastatic renal cell carcinoma have had improvements in outlook and the therapeutic options available have expanded.
PURPOSE: Our understanding of the natural history of renal cell carcinoma, the role of nephrectomy, the benefits of immunotherapy and the possibilities of new technologies are evolving and being integrated with advances in classification and staging. We reviewed the relevant literature to clarify these pertinent questions and provide a current review of the changes in the epidemiology, treatment and prognosis of patients with renal cell carcinoma. MATERIALS AND METHODS: We comprehensively reviewed the peer reviewed literature on the current management of and results of treatment for renal cell carcinoma. RESULTS: The incidence of and mortality from renal cell carcinoma have continuously increased during the last 50 years. Despite this increase in the number of new patients and consequently the number of deaths yearly the percent of those surviving for 5 years has notably improved. Factors related to improved survival include advances in renal imaging, earlier diagnosis, improved staging, better understanding of prognostic indicators, refinement in surgical technique and the introduction of immunotherapy approaches for advanced disease. CONCLUSIONS: Currently patients with localized and metastatic renal cell carcinoma have had improvements in outlook and the therapeutic options available have expanded.
Authors: Roberto Ballarin; Mario Spaggiari; Nicola Cautero; Nicola De Ruvo; Roberto Montalti; Cristina Longo; Anna Pecchi; Patrizia Giacobazzi; Giuseppina De Marco; Giuseppe D'Amico; Giorgio Enrico Gerunda; Fabrizio Di Benedetto Journal: World J Gastroenterol Date: 2011-11-21 Impact factor: 5.742
Authors: Laeeq Malik; Helen Parsons; Devalingam Mahalingam; Benjamin Ehler; Martin Goros; Alex Mejia; Andrew Brenner; John Sarantopoulos Journal: Clin Genitourin Cancer Date: 2014-02-04 Impact factor: 2.872
Authors: Joel Prince; Eric Bultman; Louis Hinshaw; Anna Drewry; Michael Blute; Sara Best; Fred T Lee; Timothy Ziemlewicz; Meghan Lubner; Fangfang Shi; Stephen Y Nakada; E Jason Abel Journal: J Urol Date: 2014-12-11 Impact factor: 7.450